Handelsbanken Fonder AB Has $21.14 Million Holdings in Natera, Inc. $NTRA

Handelsbanken Fonder AB trimmed its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 24.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 131,300 shares of the medical research company’s stock after selling 43,200 shares during the period. Handelsbanken Fonder AB’s holdings in Natera were worth $21,135,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 9.4% in the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after purchasing an additional 1,003,129 shares in the last quarter. Rakuten Investment Management Inc. acquired a new stake in Natera in the 3rd quarter valued at approximately $34,096,000. SWS Partners lifted its stake in Natera by 11.8% in the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock valued at $7,572,000 after acquiring an additional 4,980 shares in the last quarter. New York State Common Retirement Fund boosted its position in Natera by 63.2% during the 3rd quarter. New York State Common Retirement Fund now owns 148,247 shares of the medical research company’s stock worth $23,863,000 after acquiring an additional 57,400 shares during the last quarter. Finally, Vontobel Holding Ltd. grew its stake in shares of Natera by 192.5% during the 3rd quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock worth $1,373,000 after acquiring an additional 5,614 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly beat — Natera reported Q4 revenue of $665.5M and GAAP EPS of $0.35, well ahead of street estimates (revenue ~$600.7M, EPS loss consensus). The beat supports near-term growth expectations and underpins the stock’s recent strength. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Favorable clinical data — New Signatera MRD data presented at ASCO GU highlight potential utility across genitourinary cancers (including bladder preservation), which may expand clinical adoption and long-term revenue for Natera’s oncology franchise. Signatera MRD Data at ASCO GU
• Positive Sentiment: Trial results — Natera reported results from the SINERGY trial, another clinical datapoint that could support commercial adoption of its assays. Natera Announces Results From the SINERGY Trial
• Positive Sentiment: Analyst upgrades/targets — Robert W. Baird raised its price target to $257 (outperform) and Wells Fargo raised its target to $215 (equal weight), signaling some sell-side confidence in upside from current levels. Benzinga – Analyst Price Target Changes
• Neutral Sentiment: Full-year revenue guidance roughly in line with consensus — Management issued FY2026 revenue guidance (roughly $2.6B–$2.7B), which appears consistent with street expectations and reduces upside surprise potential from guidance alone. (See Q4 release for guidance details.) Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst consensus — Aggregated analyst coverage remains constructive (average “Moderate Buy”), which supports medium-term expectations but doesn’t preclude short-term volatility. Analyst Average Rating
• Negative Sentiment: Valuation and fundamentals concerns — Despite the beat, Natera still shows negative net margin and negative return on equity on a GAAP basis; combined with a high market capitalization and a recent run-up toward 52-week highs, investors may be taking profits. MarketBeat Q4 Coverage
• Negative Sentiment: Heavy intraday volume and selling pressure — Trading volume was well above average, consistent with a distribution day where some holders trimmed positions after the company’s strong quarter; that drove the stock lower despite the positives. (See intraday volume and price action for context.)

Natera Price Performance

Shares of NTRA stock opened at $208.04 on Friday. The company has a fifty day moving average price of $226.52 and a two-hundred day moving average price of $203.85. Natera, Inc. has a one year low of $125.38 and a one year high of $256.36. The stock has a market cap of $28.78 billion, a P/E ratio of -135.97 and a beta of 1.64.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 16.71%. During the same period in the previous year, the business earned ($0.41) EPS. As a group, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of research reports. Stephens boosted their price objective on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. UBS Group increased their price objective on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Finally, JPMorgan Chase & Co. lifted their target price on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average target price of $254.47.

Insider Activity

In other Natera news, CFO Michael Burkes Brophy sold 37,175 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $242.54, for a total value of $9,016,424.50. Following the sale, the chief financial officer owned 64,123 shares in the company, valued at $15,552,392.42. This represents a 36.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Solomon Moshkevich sold 23,205 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70. Following the transaction, the insider directly owned 144,992 shares in the company, valued at $34,035,422.08. The trade was a 13.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 368,119 shares of company stock valued at $85,956,782. 5.63% of the stock is owned by insiders.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.